Mangoceuticals, Inc. ( (MGRX) ) has shared an announcement.
Mangoceuticals, Inc. entered into a Debt Conversion Agreement with Mill End Capital Ltd. on January 15, 2025, converting a $150,000 debt into 100,000 shares of restricted common stock. The agreement led to the repricing of warrants and the conversion price of Series B Preferred Stock to $1.50 per share. On the same date, the company completed the final sale of 250 shares of Series B Preferred Stock to an institutional investor for $250,000. Antonios Isaac was also appointed as a new member of the Board of Directors and as President of the company.
More about Mangoceuticals, Inc.
YTD Price Performance: 4.82%
Average Trading Volume: 95,863
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.49M
Learn more about MGRX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com